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ABSTRACT 
Amoxicillin (α-amino-hydroxybenzylpenicillin) is a semi-synthetic, orally absorbed, broad-spectrum antibiotic. It is now widely used in the 
standard eradication treatment of gastric and duodenal ulcers, which are associated with H. pylori infection combined with a second antibiotic 
and an acid-suppressing agent. The aim of this study was to develop controlled release mucoadhesive microspheres of amoxicillin trihydrate for 
the treatment of gastric and duodenal ulcers caused by Helicobacter pylori (H. pylori) and evaluated anti-ulcerogenic effect of microsphere. 
Amoxicillin loaded thiolated chitosan microspheres were prepared by emulsifying method using liquid paraffin light and heavy in ratio of 50:50 
as a dispersing medium and glutaraldehyde used as a cross-linking agent. The prepared microspheres were evaluated for mean particle size 
and particle size distribution, shape and surface morphology, drug content, mucoadhesion measurement and in-vitro drug release. FT-IR 
spectroscopic analysis was performed to ascertain drug polymer interaction. Antiulcer activity of amoxicillin microspheres was investigated on 
Indomethacin induced gastric ulcer model in Albino rats. The antiulcer capability of amoxicillin microspheres was compared to  
100mg/kg cimetidine. Gastric ulcers were induced in Wistar albino rats by oral administration of indomethacin (5 mg/kg), antiulcer activity of 
amoxicillin microspheres (100, 200mg/kg, p.o) was observed on ulcer index and gastric pH. Statistical analysis was done by One-way ANOVA 
followed by Tukey’s post hoc test. The release profiles showed Korsmeyer-Peppas release behavior up to 48 hours where the highest drug 
release was 76.7±3.52% of the amoxicillin loaded in the thiolated chitosan microspheres, indicating a strong crosslinking between chitosan and 
glutaraldehyde. Amoxicillin microspheres produced significant (P<0.05) decrease in ulcer index and gastric pH as compared to control. The 
anti-ulcer effects of amoxicillin microspheres were dose dependent manner.  From the results of the present investigation it may be concluded 
that drug loaded chitosan microspheres can be prepared by a simple technique which avoids the use of complex apparat us and special 
precautions and microsphere produced significant anti-ulcer effects in experimental models. 
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INTRODUCTION 
Microsphere carrier systems made from the naturally 
occurring biodegradable polymers have attracted 
considerable attention for several years in sustained drug 
delivery. Recently, dosage forms that can precisely control 
the release rates and target drugs to a specific body site have 
made an enormous impact in the formulation and 
development of novel drug delivery systems. Microspheres 
form an important part of such novel drug delivery systems 
1-3. They have varied applications and are prepared using 
assorted polymers4. However, the success of these 
microspheres is limited, owing to their short residence time 
at the site of absorption. It would, therefore, be 
advantageous to have means for providing an intimate 
contact of the drug delivery system with the absorbing 
membranes5-8. This can be achieved by coupling 
mucoadhesion characteristics to microspheres and 
developing mucoadhesive microspheres. Mucoadhesive 
microspheres have advantages such as efficient absorption 
and enhanced bioavailability of drugs owing to a high 
surface-to volume ratio, a much more intimate contact with 
the mucus layer and specific targeting of drugs to the 
absorption site9-12. One of the polymers included in the 
multifunctional polymer is chitosan. Chitosan has 
mucoadhesive properties, permeation-enhancers, and 
enzyme-inhibitor13. Chitosan obtained from chitin 
deacetylation resulting the free amino group that can make it 
be policationic14. Chitosan has been shown to have 
mucoadhesive properties due to electrostatic interactions 
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between positively charged chitosan and negatively charged 
mucosal surface. Chitosan has one primary amino group and 
two free hydroxyl groups for each monomer. Free amino 
group in chitosan is positively charged subsequently react 
with the surface/mucus are negatively charged15. Various 
modifications have been made to the existing mucoadhesive 
polymer resulting in better mucoadhesvie properties. One 
modification is done is with the immobilization of thiol 
groups to mucoadhesive polymer so as to form disulfide 
bonds with cysteine-rich subdomains of mucus 
glycoproteins. Unlike the first generation mucoadhesive 
polymers attached to the mucus gel layer through 
noncovalent bonding, the new generation of mucoadhesive 
polymers capable of forming covalent bonds to the layer of 
mucus15. Modification of the thiol group attachment has also 
been made to the chitosan. This modification is based on the 
immobilization of thiol bearing movement on chitosan 
backbone, thus known as thiolated chitosan. This 
modification was developed to improve the solubility of 
chitosan, mucoadhesive property, and/or property of 
permeation16. Improved properties of mucoadhesive 
thiolated chitosan expected to increase the contact time of 
the drug in the gastrointestinal tract that it can increase the 
bioavailability of the drug. Helicobacter pylori (H. pylori), a 
Gram-negative human gastric bacterium, infects 
approximately 30-50% of adults in the developed world and 
over 90% of inhabitants in the developing world 17. H. pylori 
normally cause a lifelong chronic gastritis and peptic ulcer 
disease. The infection plays an important role in peptic ulcer 
disease and gastric B-cell MALT (mucosaassociated 
lymphoid tissue) lymphoma and is associated with gastric 
adenocarcinoma 18-20 and it predicted that by 2020 to enter 
the top ten of leading causes of death worldwide 21. The 
International Agency for Research and Cancer (IARC, USA) 
classified H. pylori as a group I carcinogen, a definite cause of 
human gastric cancers22. Amoxicillin (α-amino-
hydroxybenzylpenicillin) is a semisynthetic antibiotic, 
belonging to the b-Lactam family, which is effective for 
bacterial infection treatment, especially for H. pylori 
infection23. However, therapies using conventional oral 
amoxicillin capsules cannot completely eradicate H. pylori 
infections, allowing recolonization 24,25. The incomplete 
eradication of H. pylori is mainly due to the short residence 
time of antimicrobial agents in the stomach so that effective 
antimicrobial concentration cannot be achieved in the gastric 
mucous layer or epithelial cell surfaces where H. pylori exists 
26,27. The minimum inhibitory concentration of less than or 
equal to 0.01-0.1 mg/L determined in vitro implies that if 
successful local delivery were achieved, lower doses of 
antibiotic may be effective 28.  It has therefore been proposed 
that local delivery could increase drug levels in the gastric 
mucus and mucosa to effective bactericidal levels and extend 
the contact time of drugs with the organism 29. Mucoadhesive 
drug carriers may prolong the residence time in the GI tract 
because they can adhere to the mucus surface, resulting in an 
effective localized drug concentration 30. The aim of this 
work was to prepare amoxicillin trihydrate loaded 
mucoadhesive microspheres using the mucoadhesive 
polymers for H. pylori eradication therapy and evaluated 
prepared microspheres for antiulcer activity. 
MATERIALS AND METHODS 
Materials 
Amoxicillin trihydrate was obtained as gift sample from 
Sandoz Pharma Ltd. Mumbai, India. Thiolated Chitosan, 
Cimetidine and Indomethacin were acquired from Sigma-
Aldrich (St. Louis, MO, USA). Tween-80 and span-80 from 
Qualigens, Mumbai. Glacial acetic acids were purchased from 
Merck Specialties Pvt. Ltd., Mumbai, All other chemicals and 
reagent used was of analytical grade. Ultrapure water was 
used throughout the study. 
Determination of absorption maxima  
A solution of containing the concentration 30μg/ml was 
prepared in 0.1N HCl and methanol separately. UV spectrum 
was taken using double beam UV/VIS spectrophotometer 
(Labindia-3000+). The solution was scanned in the range of 
200-400nm.  
Preparation calibration curve  
Accurately weighed 10 mg of drug was dissolved in 10 ml of 
0.1N HCl and methanol solution in 10 ml of volumetric flask 
separately. The resulted solution 1000µg/ml and from this 
solution 1 ml pipette out and transfer into 10 ml volumetric 
flask and volume make up with 0.1N HCl and methanol 
solution separately. Prepare suitable dilution to make it to a 
concentration range of 10-50μg/ml. The spectrum of this 
solution was run in 200-400 nm range in U.V. 
spectrophotometer (Labindia-3000+). Linearity of standard 
curve was assessed from the square of correlation coefficient 
(r2) which determined by least-square linear regression 
analysis. 
Preparation of thiolated chitosan microsphere 
Thiolated Chitosan was selected for preparing microsphere. 
Microspheres were prepared by emulsifying method using 
liquid paraffin light and heavy in ratio of 50:50 as a 
dispersing medium and glutaraldehyde used as a cross-
linking agent. Thiolated chitosan dispersion (1.5 %w/v) was 
prepared by mixing of thiolated chitosan in glacial acetic acid 
(4%w/v) with Tween 80 (0.5% w/w). Drug was dissolved in 
chitosan solution. The prepared, 10 ml of thiolated chitosan 
solution with drug was added dropwise in a beaker 
containing 100 ml of liquid paraffin light and heavy in ratio 
of 50:50 containing Span 80 (1.0% w/v).  The system was 
kept under stirring at 3000-4000 rpm using two blade 
mechanical stirrers. 1.5 ml of glutaraldehyde saturated 
toluene was added to above solution after 30 min of stirring. 
Stirring was continued for 4hr at 40ᵒC at 4000 rpm. The 
microspheres were separated from dispersion medium by 
centrifugation and washed two times with petroleum ether 
to remove liquid paraffin and then washed three times with 
acetone. Dispersion was poured in petridish to remove 
acetone. After complete evaporation of acetone, dried drug 
loaded microsphere were collected and stored in tight 
container for further evaluation. The compositions of 
formulation were given in Table 1. 
Optimization of process Variable 
The effect of formulation process variables such as stirring 
time, stirring speed on the particle size was studied. From 
the results obtained, optimum level of those variables was 
selected and kept constant in the subsequent evaluations. 
Different amoxicillin incorporated microspheres were 
prepared using effect of Thiolated chitosan, Tween-80, Span-
80   quantity and stirring speed. The prepared microspheres 
were further evaluated for entrapment efficiency, particle 
size, zeta potential and In Vitro drug release study.  
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Table 1 Formulation optimization of microsphere 
F. Code 
Thiolated Chitosan 
(%w/v) 
Tween-80 
(%) 
Span-80 
(%) 
Stirring 
Speed 
Drug Conc. 
(% w/w) 
TCM-1 0.5 0.5 0.5 2000 - 
TCM-2 1.5 0.5 0.5 2000 - 
TCM-3 2.0 0.5 0.5 2000 - 
TCM-4 2.5 0.5 0.5 2000 - 
TCM-5 1.5 1.0 0.5 2000 - 
TCM-6 1.5 1.5 0.5 2000 - 
TCM-7 1.5 2.0 0.5 2000 - 
TCMS-8 1.5 1.0  1.0 2000 - 
TCMS-9 1.5 1.0 1.5 2000 - 
TCMS-10 1.5 1.0 2.0 2000 - 
TCMS-11 1.5 1.0 2.5 2000 - 
TCMS-12 1.5 1.0 1.5 2000 - 
TCMS-13 1.5 1.0 1.5 3000 - 
TCMS-14 1.5 1.0 1.5 4000 - 
TCMD-15 1.5 1.0 1.5 4000 10 
TCMSD-16 1.5 1.0 1.5 4000 20 
TCMSD-17 1.5 1.0 1.5 4000 30 
TCMSD-18 1.5 1.0 1.5 4000 40 
 
Evaluation of microspheres 
Measurement of mean particle size and polydispersity 
index 
Average particles size of prepared microsphere was 
determined using particle size analyser (Malvern particle 
size analyser). The microsphere formulation was diluted 
with deionized water (1:9 v/v) and analysed for average 
size. 
Shape and Surface characterization of microspheres by 
scanning electron microscopy (SEM) 
From the formulated batches of microspheres, formulations 
(TCMSD-17) which showed a suitable balance among the 
percentage releases were examined for surface morphology 
and shape using scanning electron microscope Jeol Japan 
6000. Sample was fixed on carbon tape and fine gold 
sputtering was practical in a high vacuum evaporator. The 
acceleration voltage was set at 10KV during scanning. 
Microphotographs were taken on dissimilar magnification 
and higher magnification (200X) was used for surface 
morphology.   
Determination of drug content 
The amount of drug entrapped in the microspheres was 
determined using a UV spectrophotometer. The weighed 
amount of the microspheres was incubated with 0.1 N HCl, 
pH 1.2, for 48 h. It was centrifuged at 10,000 g for 30 min 
and the supernatant was diluted 10 times before analysis 
into the UV spectrophotometer system at λmax 238nm.  
Mucoadhesion measurement study 
Mucoadhesiveness of prepared microsphere was 
determined by taking a 5-6 cm length of piece obtained from 
freshly cut pig intestine which was procured from a local 
abattoir within 1 h after sacrificed of animal. It was washed 
with isotonic saline solution. The pig intestine piece was 
attached to a polyethylene plate and placed 10 mg of 
microspheres on the mucosal surface. Plate was positioned 
at 40° angle relative to the horizontal plane. The time 
required for shedding all the microspheres from mucosal 
surface was noted. 
In Vitro drug release from microspheres  
The drug release was performed in 0.1 N HCl (1.2 pH) for 
prepared microsphere using dialysis bag technique. In this 
study suspension of microsphere equivalent to 20 mg of 
drug was taken in dialysis tubing (MWCO, 15KDa, himedia) 
and placed in a beaker containing 50ml of 0.1 N HCl (1.2 pH). 
The dialysis bag retains microsphere and allows passing of 
free drug into the dissolution media. Temperature was 
maintained at 37±10C throughout the study. The samples 
were withdrawn after specified time intervals that are 0.5, 1, 
2, 3, 4, 8, 10 and 12hrs and replaced with the same volume of 
fresh 0.1 N HCl and analyzed for drug concentration by using 
UV spectrophotometer a λmax 238nm 31-33. 
Drug release kinetic data analysis 
A number of kinetic models have been planned to explain 
the release characteristics of a drug from matrix. The next 
three equations are usually used, because of their simplicity 
and applicability. Equation 1, the zero-order model equation 
(Plotted as cumulative percentage of drug released vs time); 
Equation 2, Higuchi’s square-root equation (Plotted as 
cumulative percentage of drug released vs square root of 
time); and Equation 3, the Korsemeyer-Peppas equation 
(Plotted as Log cumulative percentage of drug released vs 
Log time). To study the release kinetics of stavudine from 
the mucoadhesive microspheres the release data was fitted 
to these three equations. 
Zero order equation 
When a graph of the cumulative percentage of the drug 
released from the matrix against time is plotted, zero order 
release is linear in such a plot, indicating that the release 
rate is independent of concentration. 
Qt = k0.t ……………………… (1) 
Where Qt is the percentage of drug released at time t and k0 is 
the releaserate constant; 
First order equation 
In (100-Qt) = In 100- kI.t ………………….. (2) 
Where kI is the release rate constant; 
Higuchi’s equation 
Qt = kH.t1/2    ……………………….. (3) 
Where KH is the Higuchi release rate constant 
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Korsemeyer-Peppas 
The curves plotted may have different slopes, and hence it 
becomes difficult to exactly pin-point which curve follows 
perfect zero order release kinetics. Therefore, to confirm the 
kinetics of drug release, data were also analyzed using 
Korsemeyer’s equation. 
                                                 Qt/Q∞ = kKP.tn 
Where Qt/ Q∞ is the fraction of drug released at time t, kKPa 
constant compromising the structural and geometric 
characteristics of the device and n is the release exponent. 
The slope of the linear curve gives the ‘n’ value. Peppas 
stated that the above equation could adequately describe the 
release of solutes from slabs, spheres, cylinders and discs, 
regardless of the release mechanism. The value of ‘n’ gives 
an indication of the release mechanism. When n = 1, the 
release rate is independent of time (typical zero order 
release / case II transport); n = 0.5 for Fickian release 
(diffusion/ case I transport); and when 0.5 < n < 1, 
anomalous (non-Fickian or coupled diffusion/ relaxation) 
are implicated. Lastly, when n > 1.0 super case II transport is 
apparent.  ‘n’ is the slope value of log Mt/M∞   versus log time 
curve 34. 
Anti-Ulcer Activity  
Animals 
30 Wistar rats of either sex weighing between 150-250 g 
were used for the study. Prior to the experiments, the rats 
were kept in the central animal house in rat cages and were 
given standard rat feed with water ad libitum. Cages were 
fitted with wire mesh floor to avoid coprophagy. 
Experimental procedures 
Indomethacin induced gastric ulcer 
Rats were divided into 4 groups of 6 each, for indomethacin 
induced gastric ulcers.  
Group –1: Control  
Group –2: Cimetidine (Standard) 
Group –3: Amoxicillin microspheres (100mg/kg, p.o.)  
Group –4: Amoxicillin microspheres (200mg/kg, p.o.) 
The animals were fasted for 24 h prior to the experiment. 
Under anaesthesia, ulcers were induced by applying 
indomethacin (5 mg/kg. p.o.) over the anterior serosal 
surface of the stomach for 60 seconds. The animals were 
treated with cimetidine (100 mg/kg, p.o.), low dose of 
amoxicillin microspheres (100 mg/kg p.o.) or high dose of 
amoxicillin microspheres (200 mg/kg p.o.) [Once daily, for 5 
days after the induction of ulcer, while the control group 
received only the vehicle]. The rats were sacrificed on the 5th 
day, the stomachs removed and cut open along the greater 
curvature35. The ulcer index was determined using the 
formula: 
Ulcer index = 10/X 
Where X = Total mucosal area/Total ulcerated area. 
Based on their intensity, the ulcers were given scores as 
follows: 
0 = no ulcer, 1 = superficial mucosal erosion, 2 = deep ulcer 
or transmural necrosis,  3 = perforated or penetrated ulcer. 
Statistical Analysis 
The data is expressed as mean ± Standard Deviation (SD). 
Results were analyzed using one-way ANOVA followed by 
Tukey’s post hoc test. Differences were considered as 
statistically significant at P < 0.05, when compared with 
control. 
RESULTS AND DISCUSSION 
The λ max of Amoxicillin was found to be 234 and 238 nm by 
using U.V. spectrophotometer (Labindia-3000+) in linearity 
range 10-50µg/ml in methanol and 0.1N HCl respectively 
Figure 1-4. The Particle size of different formulations was in 
range of 5.37±2.16-58.15±4.25µm. This is due to the 
mucoadhesion characteristics of chitosan that could 
facilitate the diffusion of part of entrapped drug to 
surrounding medium during preparation of amoxicillin 
microspheres Table 2. The amount of drug entrapped in the 
microspheres was determined using a UV 
spectrophotometer. The weighed amount of the 
microspheres was incubated with 0.1 N HCl, pH 1.2, for 48 h. 
It was centrifuged at 10,000 g for 30 min and the 
supernatant was diluted 10 times before analysis into the UV 
spectrophotometer system at λmax 238 nm Table 2. The 
results of mucoadhesiveness of prepared microsphere were 
given in Table 2. Shape and surface characteristic of 
amoxicillin microspheres examine by Scanning Electronic 
Microscopy analysis. Surface morphology of formulation 
examines at two different magnifications 55X which 
illustrate the smooth surface of microspheres Figure 5. The 
drug release rate from mucoadhesive microspheres was 
passed out using the USP type II (Electro Lab.) dissolution 
paddle instrument. A weighed amount of mucoadhesive 
microspheres equivalent to 20 mg drug were dispersed in 
900 ml of 0.1 N HCI (pH=1.2) maintained at 37±0.5°C and 
stirred at 55rpm. The release study of optimized formulation 
TCMSD-17 was given in Table 3 and Figure 6. The In vitro 
drug release data of the optimized formulation was 
subjected to goodness of fit test by linear regression analysis 
according to zero order, first order, Higuchi and Korsmeyer-
Peppas kinetic models in order to determine the mechanism 
of drug release. When the regression coefficient values of 
were compared, it was observed that ‘r’ values of 
Korsmeyer-Peppas was maximum i.e 0.926 hence indicating 
drug release from formulations was found to follow 
Korsmeyer-Peppas release kinetics Table 4, 5  and Figure 7-
10. Amoxicillin microspheres (200 mg/kg, p.o.) produced 
significant (P<0.01) increase in the gastric pH as compared 
to the control in a models of gastric ulcer. A significant 
(P<0.05) reduction in ulcer index was also observed in 
indomethacin induced ulcers. However, these effects were 
less or equal than as compared to cimetidine. In the stomach, 
prostaglandins and nitric oxide play a crucial protective role 
of stimulating the secretion of bicarbonate and mucus36, 
maintaining mucosal blood flow and regulating mucosal cells 
turnover and repairs37. Therefore, suppression of 
prostaglandin synthesis by non-steroidal anti-inflammatory 
drugs like indomethacin results in increased susceptibility to 
gastric mucosal lesions and mucosal injury 38,39 which were 
observed in indomethacin control. Amoxicillin microspheres 
at concentration of 200mg/kg significantly protected the 
mucosa from being damaged by indomethacin suggesting 
that amoxicillin mimicking prostaglandin and nitric oxide 
Table 6 and Figure 11, 12. 
 
Figure 1 Wavelength maxima of amoxicillin trihydrate in 0.1 
N HCl 
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Figure 2 Wavelength maxima of amoxicillin trihydrate in 
methanol 
 
         Figure 3 Calibration curve of amoxicillin trihydrate in 
0.1 N HCl at 238 nm 
 
Figure 4 Calibration curve of amoxicillin trihydrate in 
methanol at 234 nm 
 
Figure 5 SEM Photomicrographs of optimized formulation 
TCMSD-17
Table 2 Evaluation of amoxicillin trihydrate mucoadhesive microsphere 
F. Code PDI Particle size (µm) % Drug Entrapment Mucoadhesion time (hr.) 
TCM1 0.31±0.01 26.70±2.23 -  
TCM2 0.46±0.02 34.34±3.45 -  
TCM3 0.55±0.02 41.62±1.46 -  
TCM4 0.43±0.03 58.15±3.41 -  
TCM5 0.26±0.01 32.45±2.12 -  
TCM6 0.34±0.02 28.56±4.56 -  
TCM7 0.41±0.03 17.36±2.32 -  
TCM8 0.35±0.02 18.62±3.12 -  
TCM9 0.13±0.01 14.62±2.14 -  
TCM10 0.32±0.03 13.54±1.74 -  
TCM11 0.37±0.01 12.32±2.32 -  
TCM12 0.23±0.04 11.63±2.14 -  
TCM13 0.25±0.05 10.54±3.65 -  
TCM14 0.12±0.02 6.37±2.12 -  
TCMSD15 0.25±0.03 8.63±3.21 58.63±3.52 7.2±0.05 
TCMSD16 0.26±0.04 6.54±2.14 64.54±2.12 7.1±0.02 
TCMSD17 0.29±0.02 5.37±3.78 67.37±2.16 6.9±0.05 
TCMSD18 0.18±0.03 6.37±2.41 67.62±3.43 6.5±0.04 
 
Table 3 In vitro drug release of optimized formulation TCMSD17 
S. No. Time interval (h) Plain drug Amoxicillin Trihydrate Loaded  Microsphere 
1 0.5 26.6±1.63 5.4±0.15 
2 1 39.4±2.38 8.5±0.83 
3 2 62.8±2.35 12.6±0.52 
4 3 86.4±3.26 18.7±1.05 
5 4 99.5±3.37 26.4±1.25 
6 5 - 34.2±1.23 
7 6 - 42.4±2.09 
8 8 - 51.4±2.34 
9 12 - 60.5±3.52 
10 24 - 68.3±2.25 
11 48 - 76.7±3.52 
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Figure 6 cumulative % amoxicillin trihydrate releases 
Table 4 In-vitro drug release data for optimized formulation TCMSD-17 
Time (h) 
Square Root 
of Time(h)1/2 
Log Time 
Cumulative*% Drug 
Release 
Log Cumulative 
% Drug Release 
Cumulative %  
Drug Remaining 
Log Cumulative 
% Drug 
Remaining 
0.5 0.707 -0.301 5.4 0.732 94.6 1.976 
1 1.000 0.000 8.5 0.929 91.5 1.961 
2 1.414 0.301 12.6 1.100 87.4 1.942 
3 1.732 0.477 18.7 1.272 81.3 1.910 
4 2.000 0.602 26.4 1.422 73.6 1.867 
5 2.236 0.699 34.2 1.534 65.8 1.818 
6 2.449 0.778 42.4 1.627 57.6 1.760 
8 2.828 0.903 51.4 1.711 48.6 1.687 
12 3.464 1.079 60.5 1.782 39.5 1.597 
24 4.899 1.380 68.3 1.834 31.7 1.501 
48 6.928 1.681 76.7 1.885 23.3 1.367 
 
Table 5 Regression analysis data  
Batch 
Zero Order First Order Higuchi Korsmeyer-Peppas 
r² r² r² r² 
TCMSD-17 0.675 0.821 0.865 0.926 
 
 
Figure 7 Zero order release kinetics  
 
Figure 8 First order release kinetics  
 
Figure 9 Higuchi release kinetics  
 
Figure 10 Korsmeyer-Peppas release kinetics
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Table 6 Anti-ulcerogenic effect of amoxicillin microspheres against ulcerogenic agents in rats  
Treatment and dose Ulcer index pH 
Control 3.50 ± 5.0 1.20 ± 1.0 
Cimetidine (100 mg/kg, p.o.) 1.50 ± 5.0***  6.80 ± 1.0*** 
Amoxicillin microspheres (100 mg/kg, p.o.) 2.25 ± 5.0** 4.50 ± 1.0* 
Amoxicillin microspheres (200 mg/kg, p.o.) 1.95 ± 5.0*** 6.50 ± 1.0*** 
 
Values are expressed as mean±S.E.M. (n = 6).Percent inhibition calculated as compared to control group.***P < 0.001, ** P < 
0.01, * P < 0.05 (One-way ANOVA followed by Tukey’s post hoc test). 
 
Figure 11 Anti-ulcerogenic effect of amoxicillin microspheres against ulcerogenic agents in rats (Ulcer index) 
 
Figure 12 anti-ulcerogenic effects of amoxicillin microspheres against ulcerogenic agents in rats (pH) 
 
CONCLUSION 
From the above experimental results, it can be concluded 
that oral controlled release of amoxicillin from microspheres 
can be achieved by emulsifying method using thiolated 
chitosan as polymer and glutaraldehyde used as a cross-
linking agent. The IR spectra’s revealed that, there was no 
interaction between polymer and drug. The entire polymer 
used was compatible with the drug. Prepared microspheres 
exhibited Korsmeyer-Peppas release kinetics. The present 
study demonstrates the ulceroprotective effects of 
amoxicillin microspheres in Indomethacin-induced gastric 
ulcer model in rats by dose dependent manner. From the 
study, it is evident that a promising controlled release micro-
particulate drug delivery of amoxicillin can be developed. 
Further, in-vivo investigation is required to establish efficacy 
of these formulations.  
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